Tap any paragraph to write a margin note. Your notes collect in the Desk below the text and file under cases with @. The side-by-side margin rail opens on a larger screen.

Code · REGISTER · 2015-01-26 · DEPARTMENT OF JUSTICE · Notices

Notices. Notice of registration

293 words·~1 min read·/register/2015/01/26/2015-01306·

A research copy — for the controlling text, always check the official state or federal source. Not legal advice.

BILLING CODE P DEPARTMENT OF JUSTICE Drug Enforcement Administration [Docket No. DEA-392] Manufacturer of Controlled Substances Registration: Apertus Pharmaceuticals ACTION: Notice of registration. SUMMARY: Apertus Pharmaceuticals applied to be registered as a manufacturer of a certain basic class of controlled substance. The DEA grants Apertus Pharmaceuticals registration as a manufacturer of the controlled substance. SUPPLEMENTARY INFORMATION: By notice dated May 28, 2014, and published in the **Federal Register** on June 4, 2014, 79 FR 32321, Apertus Pharmaceuticals, 331 Consort Drive, St.
Louis, Missouri 63011, applied to be registered as a manufacturer of a certain basic class of controlled substance. No comments or objections were submitted to this notice. The Drug Enforcement Administration
(DEA)has considered the factors in 21 U.S.C. 823(a) and determined that the registration of Apertus Pharmaceuticals to manufacture the basic class of controlled substance is consistent with the public interest and with United States obligations under international treaties, conventions, or protocols in effect on May 1, 1971. The DEA investigated the company's maintenance of effective controls against diversion by inspecting and testing the company's physical security systems, verifying the company's compliance with state and local laws, and reviewing the company's background and history. Therefore, pursuant to 21 U.S.C. 823(a), and in accordance with 21 CFR 1301.33, the above-named company is granted registration as a bulk manufacturer of Remifentanil (9739), a basic class of controlled substance listed in schedule II. The company plans to manufacture small quantities of the listed controlled substance to make reference standards for distribution to their customers. On March 27, 2014, Apertus Pharmaceuticals withdrew its request for the addition of Alfentanil (9737), Sufentanil (9740), and Fentanyl
(9801)to this registration. Dated: January 9, 2015. Joseph T. Rannazzisi, Deputy Assistant Administrator. [FR Doc. 2015-01306 Filed 1-23-15; 8:45 am]
Connectionstraces to 2
Citation graph
cites case law
Notices
Notice of registration
Cites 2Cited by 0 across 0 sources
★   the supreme law of the land   ★
Don't Tread on Me
E Pluribus Unum — out of many, one

"If you don't know your rights, you don't have any."

Marginalia · a citizen's law index
A research desk, not legal advice. Always read the cited source before relying on a summary.
Questions or an issue? support@self-law.org
disclaimerMarginalia is a research index, not a law firm. Nothing on this site is legal, tax, or financial advice and no attorney–client relationship is formed by using it. Statutes, regulations, and case law change; summaries, search results, AI output, and member posts may be incomplete, out of date, or wrong. Any interpretation drawn from material on this site should be validated by a licensed attorney in your jurisdiction before you act on it.